Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
International Journal of General Medicine
|
February 18, 2022
The Value of Serum miR-139-3p Expression Level in Predicting Postoperative Survival of Colon Cancer Patients
Guohong Fu, Haimei Xu, Cong Zhou
BMC Bioinformatics
|
April 1, 2017
A neural joint model for entity and relation extraction from biomedical text
Fei Li, Meishan Zhang, Guohong Fu, et al.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
|
June 13, 2020
[Expression and clinical significance of microRNA-21-3p and microRNA-551-5p in patients with acute pancreatitis]
Kaili Wu, Lianchen Wang, Guohong Fu, et al.
Chinese Medical Journal
|
January 17, 2025
Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study
Yuankai Shi, Qingyuan Zhang, Junsheng Wang, et al.
Medcomm
|
April 23, 2026
Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open-Label, Multicenter, Phase II Study
Ting Zhou, Haishuang Sun, Gang Chen, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
International Journal of General Medicine
|
February 18, 2022
The Value of Serum miR-139-3p Expression Level in Predicting Postoperative Survival of Colon Cancer Patients
Guohong Fu, Haimei Xu, Cong Zhou
BMC Bioinformatics
|
April 1, 2017
A neural joint model for entity and relation extraction from biomedical text
Fei Li, Meishan Zhang, Guohong Fu, et al.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
|
June 13, 2020
[Expression and clinical significance of microRNA-21-3p and microRNA-551-5p in patients with acute pancreatitis]
Kaili Wu, Lianchen Wang, Guohong Fu, et al.
Chinese Medical Journal
|
January 17, 2025
Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study
Yuankai Shi, Qingyuan Zhang, Junsheng Wang, et al.
Medcomm
|
April 23, 2026
Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open-Label, Multicenter, Phase II Study
Ting Zhou, Haishuang Sun, Gang Chen, et al.
Page
of 1